EGFR and lung cancer: In this study, we reported that miR‐1‐3p and miR‐206 can overcome HGF‐induced gefitinib resistance in EGFR mutant lung cancer cells in vitro and in vivo, and the mechanisms were related to inhibit Akt/Erk pathways and meanwhile suppress HGF‐induced EMT (Figure 8).